|
Real-time Estimate
Cboe BZX
02:50:46 31/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 2.695 USD | -0.19% |
|
-3.25% | +88.73% |
| 16/10 | Edesa Biotech, Inc. Receives FDA IND Clearance For Phase 2 Clinical Study Of EB06 In Vitiligo | CI |
| 20/08 | Edesa Biotech Launches Public Offering of Common Shares, Warrants | MT |
Company Valuation: Edesa Biotech, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: September | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 97.83 | 14.25 | 13.33 | 14.45 | 17.38 | 36.48 | - | - |
| Change | - | -85.44% | -6.42% | 8.4% | 20.29% | 109.87% | - | - |
| Enterprise Value (EV) | 97.83 | 14.25 | 13.33 | 14.45 | 17.38 | 36.48 | 36.48 | 36.48 |
| Change | - | -85.44% | -6.42% | 8.4% | 20.29% | 109.87% | 0% | 0% |
| P/E | -6.71x | -0.88x | -1.51x | -2.31x | -1.94x | -1.36x | -1.31x | -1.32x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.19x | 0x | 0.1x | 0.1x | -0x | -0.33x | 1.64x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 1.57x |
| EV / Revenue | - | - | - | - | - | - | - | 1.57x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -2.04x | -1.51x | -1.11x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.7 | -7.35 | -2.93 | -1.93 | -1.27 | -1.987 | -2.067 | -2.05 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 23.26 |
| EBITDA | -23.56 | - | - | - | - | - | - | - |
| EBIT 1 | -23.68 | -18.37 | -9.223 | -7.015 | -7.912 | -17.93 | -24.13 | -32.89 |
| Net income 1 | -13.34 | -17.55 | -8.374 | -6.17 | -7.186 | -17.52 | -23.88 | -32.64 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 51.660 | 6.449 | 4.424 | 4.450 | 2.470 | 2.700 | 2.700 | 2.700 |
| Nbr of stocks (in thousands) | 1,894 | 2,209 | 3,013 | 3,247 | 7,038 | 13,512 | - | - |
| Announcement Date | 28/12/21 | 16/12/22 | 15/12/23 | 13/12/24 | 12/12/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.36x | - | - | - | 36.48M | |
| 16.97x | 6.42x | 12.3x | 1.76% | 64.38B | |
| 30.03x | 8.21x | 26.91x | 0.04% | 56.16B | |
| 37.32x | 6.62x | 19.78x | 0.87% | 54.16B | |
| 35.94x | 3.4x | 14.66x | -.--% | 45.33B | |
| 49.01x | 5.65x | 30.93x | -.--% | 42.25B | |
| -19.75x | 191.25x | -21.04x | -.--% | 40.78B | |
| 46.05x | 8.16x | 27.33x | -.--% | 33.8B | |
| 31.61x | 8.04x | 20.91x | 0.41% | 32.25B | |
| 27.18x | 5.72x | 14.84x | -.--% | 23.57B | |
| Average | 25.30x | 27.05x | 16.29x | 0.34% | 39.27B | |
| Weighted average by Cap. | 27.78x | 25.71x | 16.39x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- EDSA Stock
- Valuation Edesa Biotech, Inc.
Select your edition
All financial news and data tailored to specific country editions
